Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05892744 · ClinicalTrials.gov registry record · Phase 4
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
A Phase 4 study of Major Depressive Disorder and Chronic Major Depression, Recurrent, sponsored by University of Texas at Austin.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05892744 is a Phase 4 study of Major Depressive Disorder and Chronic Major Depression, Recurrent that is actively recruiting participants, run by University of Texas at Austin. The registered enrollment target is 50 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05892744, a Phase 4 study of Major Depressive Disorder and Chronic Major Depression, Recurrent, is actively recruiting participants, sponsored by University of Texas at Austin.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.
Conditions Studied
Interventions
- DRUG Sertraline
Study Locations (1)
Texas
- Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-09-30 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05892744
The ClinicalTrials.gov registry entry for NCT05892744 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (87% lower). The listed sponsor is University of Texas at Austin, which has 257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Sertraline is the first listed.
NCT05892744 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05892744 about?
NCT05892744 is a clinical study titled "Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression". The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is...
What is the current status of trial NCT05892744?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2023-09-30. Estimated completion is 2027-07-15.
What conditions does trial NCT05892744 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Chronic Major Depression, Recurrent.
What interventions are being tested in trial NCT05892744?
The interventions under investigation include: Sertraline (DRUG).
Who is sponsoring clinical trial NCT05892744?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05892744 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
-
Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.